# Aarti Drugs (NSE: AARTIDRUGS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AARTIDRUGS · Pivot · prices to 22 Oct 2026

Aarti Drugs (NSE: AARTIDRUGS) closed at ₹381.15 on 22 Oct 2026, down 1.51% on the day. With a market capitalisation of ₹3,479 Cr, it ranks 919th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 17.9× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has fallen 24.5%. Its 52-week range is ₹318.95 (30 Mar 2026) to ₹534.00 (10 Nov 2025); the last close is 28.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹703 Cr (+19.0% year on year) and net profit ₹50 Cr (−7.1%), on a consolidated basis. Promoters held 54.43% of the company as of 30 Jun 2026; 2.50% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹381.15 |
| Market cap | ₹3,479 Cr |
| P/E (trailing) | 17.9 |
| ROE | 12.6% (FY26) |
| ROCE | 12.9% (FY26) |
| Debt to equity | 0.37 |
| 52-week high | ₹534.00 (10 Nov 2025) |
| 52-week low | ₹318.95 (30 Mar 2026) |
| 1-year return | −24.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹703 Cr | +19.0% | ₹50 Cr | −7.1% | ₹5.49 |
| Q4 FY26 | ₹720 Cr | +6.4% | ₹55 Cr | −12.0% | ₹6.05 |
| Q3 FY26 | ₹602 Cr | +8.1% | ₹41 Cr | +9.3% | ₹4.44 |
| Q2 FY26 | ₹653 Cr | +9.1% | ₹45 Cr | +29.2% | ₹4.95 |
| Q1 FY26 | ₹591 Cr | +6.3% | ₹54 Cr | +62.2% | ₹5.91 |
| Q4 FY25 | ₹677 Cr | +9.2% | ₹63 Cr | +32.7% | ₹6.88 |
| Q3 FY25 | ₹557 Cr | −8.1% | ₹37 Cr | +1.0% | ₹4.06 |
| Q2 FY25 | ₹598 Cr | −6.7% | ₹35 Cr | −11.7% | ₹3.83 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,387 Cr | ₹168 Cr |
| FY24 | ₹2,529 Cr | ₹172 Cr |
| FY23 | ₹2,716 Cr | ₹166 Cr |
| FY22 | ₹2,489 Cr | ₹205 Cr |
| FY21 | ₹2,155 Cr | ₹280 Cr |
| FY20 | ₹1,806 Cr | ₹141 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 54.43%
- Foreign institutions: 1.52%
- Domestic institutions: 10.29%
- Non-institutions: 33.75%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | ₹401.55 | ₹4,027 Cr | 62.7 | — |
| [Gujarat Themis Biosyn](https://app.pivotnow.in/stock/GUJTHEM) | ₹365.70 | ₹3,985 Cr | 85.4 | — |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | ₹495.95 | ₹3,492 Cr | 13.8 | — |
| [Solara Active Pharma Sciences](https://app.pivotnow.in/stock/SOLARA) | ₹650.75 | ₹3,140 Cr | — | — |
| [Ind-Swift Laboratories](https://app.pivotnow.in/stock/INDSWFTLAB) | ₹347.05 | ₹3,018 Cr | 71.6 | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |

## Questions and answers

### What is the share price of Aarti Drugs today?

Aarti Drugs (NSE: AARTIDRUGS) last closed at ₹381.15 on 22 Oct 2026. Its 52-week high is ₹534.00 and its 52-week low is ₹318.95.

### What is the market cap of Aarti Drugs?

Aarti Drugs' market capitalisation is ₹3,479 Cr (₹3,479 Cr) at the 22 Oct 2026 close, ranking 919th among the NSE companies Pivot tracks.

### What is the P/E ratio of Aarti Drugs?

Aarti Drugs trades at a trailing P/E of 17.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 62.7.

### What is the ROE and ROCE of Aarti Drugs?

Return on equity was 12.6% in FY26 and return on capital employed was 12.9% in FY26 (consolidated figures).

### Is Aarti Drugs a debt-free company?

No. Aarti Drugs' debt-to-equity ratio was 0.37 in FY26, with total debt of ₹257 Cr.

### What were Aarti Drugs' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Aarti Drugs reported revenue of ₹703 Cr, +19.0% year on year, and net profit of ₹50 Cr, −7.1% year on year.

### How has Aarti Drugs stock performed over the last year?

Aarti Drugs' share price has fallen 24.5% over the past year, −7.3% over three months and −12.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Aarti Drugs?

As of 30 Jun 2026: promoters 54.43%, foreign institutions 1.52%, domestic institutions 10.29%, non-institutions 33.75%. 2.50% of promoter shares were pledged.

### Who are Aarti Drugs' competitors?

The listed Pharma & Healthcare companies closest to Aarti Drugs by market cap are Gufic Biosciences, Gujarat Themis Biosyn, Unichem Laboratories, Solara Active Pharma Sciences, Ind-Swift Laboratories and Advanced Enzyme Technologies.

### Is Aarti Drugs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aarti Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AARTIDRUGS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.